An approach to explain the Isomangiferin higher clonogenic potential of HSPCs from PCB might be the fluctuating cytokine and chemokine levels in neonates that reflect the transfer of hematopoiesis from liver to bone marrow, which may vary in certain preterm newborns. Cord blood from term newborns exhibit a higher WBC count than those from preterm newborns. Although TCB possesses a higher WBC count, we measured a fewer HSPC concentration compared to preterm cord blood, which is in contrast to other studies. This might be explained by different used enumeration methods. In our study, we used a lyse-no-wash whole blood assay without prior cell separation or enrichment step minimizing cell loss. To date, the influence of maternal age on cord blood HSPCs is disputable. As described by Schisandrin-C others, maternal age had no impact on the HSPC concentration. In contrast, other groups reported an influence of maternal age on HSPC concentration, which is in line with our results. In addition, the univariate analysis shows a maternal age-dependent influence on the clonogenic capacity. The etiology for this finding is unclear. Speculative hypotheses include alternating fetal hormone levels during pregnancy. Interestingly, we found no clinical correlation of premature birth associated morbidities on HSPC count and clonogenic capacity. In our study, preeclampsia and small-for-gestational-age did not affect the cord blood HSPC concentration as described by other groups and may be due to our small sample size. Although tocolysis with Atosiban had no effect on the HSPC population, the influence of magnesium sulfate on CD34+ cells, which is widely used as tocolytic drug in the U.S., is still unknown. In 1997, Yin et al. identified the novel stem cell marker CD133 restricted to a subset of CD34+ HSPC with long-term repopulating ability. The indicated role of HSPC subsets in tissue repair and the sufficient isolation from UCB may suggest a therapeutic capacity of different HSPC subsets in regenerative medicine. Taguchi et al. showed that the systemic administration of CD34+ HSPCs promote the neovascularization and enhance the neurogenesis in a mouse stroke model.